Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 863.35M P/E 5.09 EPS this Y -75.90% Ern Qtrly Grth -
Income 145.42M Forward P/E 11.56 EPS next Y 115.10% 50D Avg Chg 2.00%
Sales 330.5M PEG 1.85 EPS past 5Y -3.40% 200D Avg Chg 4.00%
Dividend N/A Price/Book 1.55 EPS next 5Y 19.34% 52W High Chg -11.00%
Recommedations 2.50 Quick Ratio 11.03 Shares Outstanding 62.56M 52W Low Chg 24.00%
Insider Own 1.07% ROA 8.52% Shares Float 50.38M Beta 0.58
Inst Own 119.71% ROE 23.83% Shares Shorted/Prior 11.71M/11.40M Price 13.18
Gross Margin 90.37% Profit Margin 44.00% Avg. Volume 669,608 Target Price 18.00
Oper. Margin 54.74% Earnings Date Oct 30 Volume 542,807 Change -1.35%
About Innoviva, Inc.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Innoviva, Inc. News
11/26/24 Innoviva to Participate in the Citi 2024 Global Healthcare Conference
11/21/24 Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity
11/12/24 Innoviva to Participate in the UBS Global Healthcare Conference
11/08/24 Innoviva Third Quarter 2024 Earnings: EPS: US$0.019 (vs US$1.26 in 3Q 2023)
11/06/24 Innoviva: Q3 Earnings Snapshot
11/06/24 Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
09/30/24 Innoviva, Inc.'s (NASDAQ:INVA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
09/04/24 Innoviva to Participate in Upcoming Investor Conferences
07/31/24 Innoviva: Q2 Earnings Snapshot
07/31/24 Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
07/17/24 Innoviva (NASDAQ:INVA) shareholders have earned a 36% return over the last year
07/09/24 The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
06/27/24 3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge
06/18/24 Apple downgraded, Kroger upgraded: Wall Street's top analyst calls
06/06/24 Calculating The Fair Value Of Innoviva, Inc. (NASDAQ:INVA)
06:00 AM Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
05/31/24 3 Under-$20 Stocks That Could Make You a Fortune
05/10/24 Innoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed Analysis
05/10/24 Innoviva First Quarter 2024 Earnings: EPS: US$0.58 (vs US$0.51 in 1Q 2023)
05/08/24 Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
INVA Chatroom

User Image YawningKitty Posted - 1 day ago

🎅 Santa Rally Incoming? Russell 2000 Steals the Spotlight! $DJI $SPX US stock indices are mostly in the green last week, with the Dow Jones leading the way. Asian markets are up too, but Europe? Not so much. On a monthly basis, the US is still crushing it compared to other regions. $IWM One standout is the Russell 2000, which jumped 10% in November. That's its best month since July 2024, when it also popped 10%. Makes sense, though—Trump’s second term is expected to be a boost for small and mid-sized US companies, and the Russell 2000 reflects that. Here’s the kicker: the Russell’s post-election performance this year is tracking pretty close to its 2016 post-election rally, back when Trump won his first term. Even compared to the S&P 500 (which is doing better than it did in 2016), the Russell 2000 seems to have some serious momentum behind it. And don’t forget the classic Santa Claus rally! Historically, risky assets tend to run hot as the year wraps up, with the rally often kicking off right after Thanksgiving. Looking at 33 years of data, the S&P 500 has ended December in the green 76% of the time, averaging a 1.6% gain. The Russell 2000? Even better—positive 79% of the time with an average 3% gain. Election years are an even bigger deal. Since 1991, the S&P 500 has finished up in six out of eight election years, averaging a 1.4% return. But the Russell 2000? A perfect 8/8, with a massive average gain of 4.7%! As the Russell 2000 soars with its best monthly performance, it's the perfect time to explore some hidden gems in the small-cap space! Here are three high-potential stocks: 1.$APPF (AppFolio, Inc.) AppFolio focuses on property management software, offering super-efficient SaaS solutions that are a hit with small and mid-sized property managers. With the growing demand for digital tools in real estate, their platform is gaining traction. 2.$BGM (BGM Group Ltd.) BGM is a global pharmaceutical and chemical company, and its diversified investment strategy has helped it delve into several emerging markets. The company's strategic acquisitions and investments are expected to drive even more value for shareholders down the line. The recent dip in price could be a great opportunity to get in at a discount. 3.$INVA (Innoviva, Inc.) Innoviva is all about drug development, working with big pharma partners to deliver innovative therapies. Most of their revenue comes from royalties on inhaled medications, and they have solid partnerships with top-tier pharma companies. With a low P/E ratio and strong profitability, this one’s a hidden gem in the biotech space. Could this year be more of the same? Let’s see if the Santa Rally delivers again! 🎄📊Always DYOR, and happy investing! 📈

User Image AlexDennerShouldBuyPLX Posted - 11/24/24

$PLX $PINS $INVA Dear Santa, This is my grown up Christmas List! 1. For Alex Denner and Sarissa CM to make a large scale investment in $PLX. 2. For Steven Cohen and Point72 AM to make a large scale investment in $PLX. Respectfully, Robby Hart the Wedding Singer

User Image UncleStock Posted - 11/22/24

$SIGA $SMLR $HRMY $INVA suggested for Health Care - value screen: https://zpr.io/w3j8HS7Eft4n

User Image UncleStock Posted - 11/20/24

$SIGA $HRMY $INVA $EXEL suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN

User Image NVDAMillionaire Posted - 11/17/24

$INVA Innoviva (INVA): Diversifying Beyond Respiratory Royalties to Drive Long-Term Value https://beyondspx.com/article/innoviva-inc-nasdaq-inva-a-diversified-healthcare-powerhouse-delivering-robust-growth

User Image All4Retiring Posted - 11/12/24

$INVA Please do your due diligence on Zoliflodacin. Impressive asset for INVA

User Image Doozio Posted - 11/12/24

INTA or $inva 🧠⏰♾️

User Image JFDI Posted - 11/12/24

$INVA going stage 2.... @Doozio this one of yours?

User Image SCCT2FL Posted - 11/12/24

$INVA what has this up today?

User Image UncleStock Posted - 11/12/24

$SIGA $SMLR $HRMY $INVA suggested for Health Care - value screen: https://zpr.io/w3j8HS7Eft4n

User Image Estimize Posted - 11/07/24

Wall St is expecting 0.35 EPS for $INVA Q4 [Reporting 02/05 AMC] http://www.estimize.com/intro/inva?chart=historical&metric_name=eps&utm_co

User Image All4Retiring Posted - 11/07/24

$INVA https://www.businesswire.com/news/home/20241106330461/en/Innoviva-Reports-Third-Quarter-2024-Financial-Results-Highlights-Recent-Company-Progress/

User Image King_S Posted - 11/07/24

MYNZ moving +12.25% in PM and opening climbing up same with volume 🚀 All is buying, ready for the squeeze. HUGE PR drop incoming before the Nov 13 meeting, so compliance is coming, no RS needed. $PHVS $PRAX $INVA

User Image Wigglyick Posted - 10/30/24

@DonCorleone77 I have $BECN $RSI $CTSH $INVA reporting after close.

User Image Estimize Posted - 10/28/24

Wall St is expecting -72.96% YoY EPS growth for $INVA in Q3, up from -2850.00% in Q2 [Reporting 10/30 AMC] http://www.estimize.com/intro/in

User Image UncleStock Posted - 10/26/24

$SIGA $HRMY $INVA $UTHR suggested for $NBI US NASDAQ Biotechnology - value screen: https://zpr.io/tBVec

User Image FlynancialAnalyst Posted - 10/19/24

$INVA Keep an eye on this $1.25B mc $XBI name knocking on key $20 level from below for the 4th time over the past 10yrs Short float % is trending lower relative to YTD highs 26.05% Pct of all funds long shares is 1.5yr highs & rising TrendEdge.app/asset/INVA

User Image All4Retiring Posted - 10/17/24

$INVA Great upside here with Zoliflodacin FDA NDA filing in early 2025

User Image WeeklyTrader Posted - 10/16/24

Who’s jumping in on $INVA? RSI: 61.12% 50-day MA: $19.13 200-day MA: $16.72

User Image UncleStock Posted - 10/15/24

$SIGA $SMLR $INVA $OSUR suggested for Health Care - value screen: https://zpr.io/w3j8HS7Eft4n

User Image UncleStock Posted - 10/13/24

$SIGA $INVA $HRMY $UTHR suggested for $NBI US NASDAQ Biotechnology - value screen: https://zpr.io/tBVec

User Image UncleStock Posted - 10/10/24

$SIGA $INVA $HRMY $UTHR suggested for $NBI US NASDAQ Biotechnology - value screen: https://zpr.io/tBVec

User Image UncleStock Posted - 10/07/24

$SIGA $INVA $HRMY $TCNNF suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN

User Image StockConsultant Posted - 09/30/24

$INVA Innoviva stock, good day off the 18.98 triple support area

User Image UncleStock Posted - 09/28/24

$SIGA $INVA $HRMY $UTHR suggested for $NBI US NASDAQ Biotechnology - value screen: https://zpr.io/tBVec

User Image UncleStock Posted - 09/27/24

$SIGA $INVA $HRMY $UTHR suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN

User Image All4Retiring Posted - 09/27/24

$INVA Countdown to the Zolidflodacin FDA NDA filing early in 2025. Potential annual sales in the USA is $500 million per year.

User Image UncleStock Posted - 09/24/24

$LPG $AMR $INVA $ENVA suggested for $SML US S&P Small-Cap 600 Index - value screen: https://zpr.io/tQPv2

User Image PenkeTrading Posted - 09/17/24

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Innoviva Inc. Is that bullish or bearish? $INVA #Innoviva #RsiOverbought #NASDAQ

User Image StockInvest_us Posted - 09/16/24

Signal alert: $INVA - Oversold Trend Short (Undervalued) https://stockinvest.us/l/iPVXlpW5sS

Analyst Ratings
Cantor Fitzgerald Overweight Aug 1, 24
Cantor Fitzgerald Overweight Jul 30, 24
Cantor Fitzgerald Overweight Jun 20, 24
Cantor Fitzgerald Overweight Jun 18, 24
EF Hutton Buy May 10, 23
EF Hutton Buy Apr 20, 23
Goldman Sachs Neutral Mar 3, 23
Morgan Stanley Underweight Mar 3, 23
EF Hutton Buy Mar 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
DENNER ALEXANDER J 10% Owner 10% Owner Jun 05 Buy 13.05 15,000 195,750 7,215,000 06/07/23
DENNER ALEXANDER J 10% Owner 10% Owner May 25 Buy 13.07 200,000 2,614,000 7,200,000 05/30/23
DENNER ALEXANDER J 10% Owner 10% Owner May 17 Buy 13.2 96,000 1,267,200 7,000,000 05/19/23
DENNER ALEXANDER J 10% Owner 10% Owner May 11 Buy 12.3359 290,000 3,577,411 6,904,000 05/15/23
Raifeld Pavel Chief Executive Offi.. Chief Executive Officer Mar 10 Buy 10.8677 3,000 32,603 9,799 03/14/23
Bickerstaff George Director Director May 25 Buy 13.21 20,000 264,200 124,560 05/25/21